Novavax, Inc. (NVAX) Income Statement

The revenue trajectory is highly erratic, with a massive spike in 2025Q1 likely driven by seasonal vaccine sales, followed by a sharp contraction. The -76.3% year-over-year decline in 2026Q2 suggests the company is struggling to find a stable revenue base post-pandemic. Investors should monitor whether new product launches or partnerships can provide a more predictable revenue stream.

The gross margin fluctuations are stark, with high margins during peak demand periods and much lower margins during off-peak quarters. This suggests that Novavax's pricing power is highly dependent on the urgency of demand and the mix of products sold. The 74.9% gross margin in 2026Q2, while still high, is below the 2025Q1 peak, implying potential pricing pressure or a shift toward lower-margin products.

The operating leverage is extreme, with fixed R&D and SG&A costs remaining relatively stable while revenue fluctuates dramatically. In 2025Q1, the high revenue more than covered these costs, but in 2026Q2, the revenue collapse left the company deeply unprofitable. This indicates that Novavax's cost structure is not flexible enough to adapt to rapid demand changes, a key risk for investors.

R&D spending has remained high, ranging from $70.7M to $106.9M, regardless of revenue levels. This suggests that Novavax is prioritizing long-term innovation over short-term profitability, which is typical for biotech but risky given the revenue volatility. SG&A costs have also been cut significantly in 2026Q2 to $0, which may indicate a strategic shift or cost-cutting measures, but the sustainability of such cuts is uncertain.

The 2025Q1 quarter was the inflection point, representing the height of COVID vaccine sales. The subsequent decline in revenue and profitability highlights the company's over-reliance on a single product and the challenges of transitioning to a sustainable business model. The lasting impact is a volatile earnings profile that makes valuation and forecasting difficult.